¹ÙÀÌ·¯½º°£¿° Ä¡·áÀÇ ÃÖ½ÅÁö°ß : 2023-12-16
±³À°ÀÏÀÚ : 2023-12-16
±³À°Àå¼Ò : °í·Á´ëÇб³ ±¸·Îº´¿ø »õ·Ò±³À°°ü ´ë°´ç
±³À°ÁÖÁ¦ : ¹ÙÀÌ·¯½º°£¿° Ä¡·áÀÇ ÃÖ½ÅÁö°ß
ÁÖÃÖ±â°ü : ´ëÇÑ°£ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¹ÙÀÌ·¯½º°£¿° ¿¬±¸È¸
´ã´çÀÚ : ´ëÇÑ°£ÇÐȸ
¿¬¶ôó : 02-707-0091
À̸ÞÀÏ : kasl@kams.or.kr
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀÎ : 50¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 12¿ù 16ÀÏ °í·Á´ëÇб³ ±¸·Îº´¿ø »õ·Ò±³À°°ü ´ë°´ç 13:35~14:00 Clinical Insights into Novel Viral Markers for Outcome Prediction in CHB ±èÅÂÇü(ÇѸ²´ë)
±³À°½Ã°£ 12¿ù 16ÀÏ °í·Á´ëÇб³ ±¸·Îº´¿ø »õ·Ò±³À°°ü ´ë°´ç 14:00~14:25 Novel strategies for anti-HBV nucleos(t)ide analogues treatment ÃÖ¿ø¹¬(¿ï»ê´ë)
±³À°½Ã°£ 12¿ù 16ÀÏ °í·Á´ëÇб³ ±¸·Îº´¿ø »õ·Ò±³À°°ü ´ë°´ç 14:25~14:50 Cardiovascular Risk Factors after Hepatitis C Virus Eradication with Direct-Acting Antivirals ÀåÀº¼±(¼¿ï´ë)
±³À°½Ã°£ 12¿ù 16ÀÏ °í·Á´ëÇб³ ±¸·Îº´¿ø »õ·Ò±³À°°ü ´ë°´ç 14:50~15:15 Experimental studies targeting for functional and sterlizing cure for CHB ±è±Õȯ(¼º±Õ°ü´ë)
±³À°½Ã°£ 12¿ù 16ÀÏ °í·Á´ëÇб³ ±¸·Îº´¿ø »õ·Ò±³À°°ü ´ë°´ç 15:50~16:10 Hepatitis B : update based on the current therapy ÀÌÀç½Â(¿¬¼¼´ë)
±³À°½Ã°£ 12¿ù 16ÀÏ °í·Á´ëÇб³ ±¸·Îº´¿ø »õ·Ò±³À°°ü ´ë°´ç 16:10~16:30 Hepatitis B : novel therapeutic agents ±èÈñ¾ð(°¡Å縯´ë)
±³À°½Ã°£ 12¿ù 16ÀÏ °í·Á´ëÇб³ ±¸·Îº´¿ø »õ·Ò±³À°°ü ´ë°´ç 16:30~16:50 Hepatitis C, D, others and coinfection °¿ø¼®(¼º±Õ°ü´ë)
±³À°½Ã°£ 12¿ù 16ÀÏ °í·Á´ëÇб³ ±¸·Îº´¿ø »õ·Ò±³À°°ü ´ë°´ç 16:50~17:00 An artificial intelligence model for prediction of hepatocellular carcinoma development after oral antiviral therapy in patients with chronic hepatitis C ÀÌÀ¯¸²(°æºÏ´ë)
±³À°½Ã°£ 12¿ù 16ÀÏ °í·Á´ëÇб³ ±¸·Îº´¿ø »õ·Ò±³À°°ü ´ë°´ç 17:00~17:10 Influence of viral load and fibrotic burden on hepatocellular carcinoma risk at phase change to immune-active phase in chronic hepatitis B ÀüÈ£¼ö(ÀÌÈ¿©´ë)